计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S126061-250mg |
250mg |
现货 ![]() |
| |
| S126061-1g |
1g |
现货 ![]() |
| |
| S126061-5g |
5g |
现货 ![]() |
| |
| S126061-25g |
25g |
现货 ![]() |
|
| 别名 | 舒尼替尼 |
|---|---|
| 英文别名 | 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- | D08552 | C22H27FN4O2 | N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide | SC |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Sunitinib |
| 生化机理 | IC50 值:2 nM(PDGFRβ);80 nM(VEGFR2)[1] 舒尼替尼是一种多靶点 RTK 抑制剂,靶向 VEGFR2 (Flk-1) 和 PDGFRβ,IC50 值分别为 80 nM 和 2 nM,在体外还能抑制 c-Kit:舒尼替尼是 VEGFR2 (Flk1) 和 PDGFRβ 的强效 ATP 竞争性抑制剂,Ki 分别为 9 nM 和 8 nM,对 VEGFR2 和 PDGFR 的选择性比 FGFR-1、EGFR、Cdk2、Met、IGFR-1、Abl 和 src 高 10 倍以上。在血清饥饿的表达 VEGFR2 或 PDGFRβ 的 NIH-3T3 细胞中,舒尼替尼抑制 VEGF 依赖性 VEGFR2 磷酸化和 PDGF 依赖性 PDGFRβ 磷酸化的 IC50 分别为 10 nM 和 10 nM。舒尼替尼可抑制 VEGF 诱导的血清饥饿 HUVEC 增殖,IC50 为 40 nM;可抑制 PDGF 诱导的过表达 PDGFRβ 或 PDGFRα 的 NIH-3T3 细胞增殖,IC50 分别为 39 nM 和 69 nM [2]。SU11248 对野生型 FLT3(FLT3-WT)、FLT3-ITD 和 FLT3 激活环(FLT3-Asp835)突变体的磷酸化也有很强的活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 成纤维细胞生长因子受体 1 抑制剂;FMS 相关受体酪氨酸激酶 3 抑制剂;FMS 相关受体酪氨酸激酶 4 抑制剂;激酶插入域受体抑制剂;KIT 原癌基因受体酪氨酸激酶抑制剂;血小板衍生生长因子受体 beta 抑制剂;ret 原癌基因抑制剂 |
| 产品介绍 |
Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488195369 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| INCHI | 1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12- |
| InChi Key | WINHZLLDWRZWRT-ATVHPVEESA-N |
| Smiles | CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C |
| Isomeric SMILES | CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C |
| PubChem CID | 5329102 |
| UN Number | 2811 |
| Packing Group | III |
| 分子量 | 398.47 |
| 溶解性 | 25°C: DMSO |
|---|---|
| 分子量 | 398.500 g/mol |
| XLogP3 | 2.600 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 398.212 Da |
| 单同位素质量Monoisotopic Mass | 398.212 Da |
| 拓扑极表面积Topological Polar Surface Area | 77.200 Ų |
| 重原子数Heavy Atom Count | 29 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 636.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS06 |
|---|---|
| 信号词 | 危险 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 | |
| 分析证书 | S126061 |
¥117.52
| 1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB et al.. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.. Clin Cancer Res, 9 (1): (327-37). [PMID:12538485] |
| 2. Khanwelkar RR, Chen GS, Wang HC, Yu CW, Huang CH, Lee O, Chen CH, Hwang CS, Ko CH, Chou NT et al.. (2010) Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.. Bioorg Med Chem, 18 (13): (4674-86). [PMID:20570526] |
| 3. Dongjie Li, Chengzhu Song, Chunpu Song, Xinrui Tian, Huaibo Zhang, Jie Zhang, Xiaoyan Zhao. (2024) Sunitinib induces cardiotoxicity through modulating oxidative stress and Nrf2-dependent ferroptosis in vitro and in vivo. CHEMICO-BIOLOGICAL INTERACTIONS, 388 (110829). [PMID:38101598] [10.1016/j.cbi.2023.110829] |
| 4. Xianzhou Huang, Lu Li, Chunqing Ou, Meiling Shen, Xinchao Li, Miaomiao Zhang, Rui Wu, Xiaorong Kou, Ling Gao, Furong Liu, Rui Luo, Qinjie Wu, Changyang Gong. (2023) Tumor Environment Regression Therapy Implemented by Switchable Prune-to-Essence Nanoplatform Unleashed Systemic Immune Responses. Advanced Science, (2303715). [PMID:37875395] [10.1002/advs.202303715] |
| 5. Yingping Zeng, Shufen Zhang, Sufen Li, Guangtao Song, Tingting Meng, Hong Yuan, Fuqiang Hu. (2023) Normalizing Tumor Blood Vessels to Improve Chemotherapy and Inhibit Breast Cancer Metastasis by Multifunctional Nanoparticles. MOLECULAR PHARMACEUTICS, 20 (10): (5078–5089). [PMID:37728215] [10.1021/acs.molpharmaceut.3c00381] |
| 6. Fangjun Chen, Wenda Chen, Zhenxin Wang, Yingfei Peng, Beili Wang, Baishen Pan, Wei Guo. (2023) Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma. Journal of Mass Spectrometry and Advances in the Clinical Lab, 29 (2). [PMID:37234251] [10.1016/j.jmsacl.2023.05.001] |
| 7. Yingping Zeng, Tong Yu, Shufen Zhang, Guangtao Song, Tingting Meng, Hong Yuan, Fuqiang Hu. (2022) Combination of tumor vessel normalization and immune checkpoint blockade for breast cancer treatment via multifunctional nanocomplexes. Biomaterials Science, 10 (15): (4140-4155). [PMID:35726757] [10.1039/D2BM00600F] |
| 8. Zhiguang Fu, Hongqi Li, Peng Xue, Hanying Yu, Shuo Yang, Cheng Tao, Wei Li, Yingjie Wang, Jianjun Zhang, Yu Wang. (2022) Implantable Bioresponsive Hydrogel Prevents Local Recurrence of Breast Cancer by Enhancing Radiosensitivity. Frontiers in Bioengineering and Biotechnology, 10 (881544). [PMID:35497337] [10.3389/fbioe.2022.881544] |
| 9. Hou Bolin, Wang Gang, Gao Quan, Wei Yanjie, Zhang Caining, Wang Yange, Huo Yuqing, Yang Huaiyi, Jiang Xuejun, Xi Zhijun. (2019) SQSTM1/p62 loss reverses the inhibitory effect of sunitinib on autophagy independent of AMPK signaling. Scientific Reports, 9 (1): (1-13). [PMID:31366950] [10.1038/s41598-019-47597-4] |
| 10. Gao Ningning, Zhong Jingjing, Wang Xiaodong, Jin Zhenchao, Li Wang, Liu Yu, Diao Yuwen, Wang Zhulin, Jiang Wenqi, Jin Guangyi. (2016) Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. Scientific Reports, 6 (1): (1-9). [PMID:28000738] [10.1038/srep39598] |
| 11. Wei Li, Yan Wang, Hongkun Miao, Maohui Yan, Chen Liu, Yu Wang, Jianjun Zhang, Zhiguang Fu. (2025) Application of MMP-2-responsive in situ forming injectable hydrogel in preventing the recurrence of oral squamous cell carcinoma. RSC Advances, 15 (3): (1507-1513). [PMID:39831041] [10.1039/D4RA06120A] |
| 12. Qianqian Wang, Yuanyuan Zheng, Bowen Deng, Di Chen, Liuqun Jia, Nian Shi. (2024) Automated kapok fiber-based pipette-tip solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry for rapid and sensitive analysis of tyrosine kinase inhibitors in plasma. JOURNAL OF CHROMATOGRAPHY A, 1736 (465420). [PMID:39378625] [10.1016/j.chroma.2024.465420] |
| 13. Jing Ye, Yuanyuan Zheng, Xiangyu Li, Xingyi Jiang, Di Chen. (2024) Melt-blown polypropylene nonwoven as an efficient and eco-economic sorbent for pipette tip micro-solid phase extraction for the determination of tyrosine kinase inhibitors. ANALYTICA CHIMICA ACTA, 1329 (343240). [PMID:39396303] [10.1016/j.aca.2024.343240] |
| 14. Qianqian Wang, Yuwei Liu, Yuanyuan Zheng, Di Chen, Ya Xie, Nian Shi. (2024) MonoTip C18 pipette tip solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry enables rapid and automated therapeutic drug monitoring of tyrosine kinase inhibitors. Arabian Journal of Chemistry, 17 (105976). [10.1016/j.arabjc.2024.105976] |
| 15. Ruyi Lin, Jia Yan, Bokai Gong, Fan Tong, Yujun Song, Xue Xia, Haili Hu, Yufan Wang, Yang Zhou, Tao Gong, Maxim Shevtsov, Huile Gao. (2024) Self-Delivered Transformable Nanosystem Capable of Enhancing Photodynamic Effectiveness and Multi-Target Ameliorating Immunosuppression for Treatment of Breast Cancer and Lung Metastasis. ADVANCED FUNCTIONAL MATERIALS, (2405051). [10.1002/adfm.202405051] |
| 16. Guang-rong Lu, Rui-zhen Wang, Xin-yu Zhao, Jun-er Xu, Cheng-ke Huang, Wei Sun, Rui-jie Chen, Zhe Wang. (2024) The CYP3A inducer dexamethasone affects the pharmacokinetics of sunitinib by accelerating its metabolism in rats. CHEMICO-BIOLOGICAL INTERACTIONS, 403 (111228). [PMID:39244184] [10.1016/j.cbi.2024.111228] |